New Immunotherapy Developed by Chilean Doctor Offers Hope To Fight Against Cancer

The new immunotherapy cancer treatment is in the pre-clinical stage and awaits to be patented in the United States before progressing to other stages.

A new immunological therapy that fights against cancer cells in humans by increasing the body’s anti-tumor response was presented in Santiago city in Chile.

The therapy is in the pre-clinical stage and its creator, Claudio Acuna, a researcher at the University of Santiago, has said the therapy will soon be patented in the United States.

Rationale for Use of Targeted Immunotherapy in Sarcomatoid Lung Carcinomas Highlighted
Rare subtypes of poorly differentiated non–small-cell lung carcinomas of high grade and aggressive behavior are observed in sarcomatoid carcinomas of the lung.

Acuna said, “The aim is to generate a vaccine for people who already are showing signs of cancer which will allow them to improve their immunological response against tumors. We do not expect to reverse the cancer but offer an alternative".

"We need to wait for patents approval before progressing to the other stages. Our project is focused on improving the quality of life of the patients in the long term and to generate a therapy that is supplementary to the conventional treatments."

This new method could decrease global medical care costs by 70 percent in comparison with similar therapies.

Immunotherapy Shows Remarkable Success Even in Difficult-to-Treat Cancers
In some cases, immunotherapy has been shown to completely eradicate cancer and has proved to be successful in treating cancers of the lung, liver, head or neck.

"This immunotherapy is available for a wide spectrum of patients with breast, skin, lung, colon, and prostate cancer in the advanced stages," Acuna said.

"It will not have any side-effects and in terms of cost, once it's marketed, it will not cost more than $750."

Immunotherapy Could Stop Resistance to Radiotherapy: Research
Treating cancers with immunotherapy and radiotherapy at the same time could stop them from becoming resistant to treatment, claims a study published in Cancer Research*.

Every year, more than 10 million people in the world are diagnosed with new cases of cancer, according to the World Health Organization (WHO). In 2012, 8.2 million people died from the disease.

Source-IANS

Anti-CTLA-4 Cancer Immunotherapy Outcome Predicted With T Cell Repertoire Changes
Effects of anti-CTLA-4 antibody on the number and types of T cells present in patient's blood was investigated using LymphoSIGHT™ immune repertoire sequencing platform.